Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN003694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer

NCT05950464 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT05950464
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05950464 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN003694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Recruiting
Start date
December 18, 2023
Completion date
June 30, 2027
Enrollment
65 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent endometrial carcinoma, recurrent endometrial clear cell adenocarcinoma, recurrent endometrial endometrioid adenocarcinoma, recurrent endometrial low grade endometrioid adenocarcinoma, recurrent ovarian clear cell adenocarcinoma, recurrent ovarian endometrioid adenocarcinoma, recurrent ovarian high grade serous adenocarcinoma, recurrent ovarian low grade endometrioid adenocarcinoma, recurrent platinum-resistant ovarian carcinoma